Nanjing Leads Biolabs Co., Ltd.
EA Policies for Single Patient
Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “the Company”) conducts clinical trials to evaluate the safety and efficacy of its investigational products. The Company believes that participation in well-designed clinical trials is the most appropriate way for patients to access our investigational medicinal products prior to regulatory approval.
Based on the current stage of clinical development and the ongoing assessment of safety profile of IMPs, our IMPs will not be provided for expanded access at this time.